{
    "ticker": "CDTX",
    "name": "Codiak BioSciences, Inc.",
    "description": "Codiak BioSciences, Inc. is an innovative biotechnology company focused on the advancement of exosome-based therapies to transform the treatment of cancer and other serious diseases. Founded in 2015, Codiak leverages its proprietary exosome engineering platform to develop a new class of biologics known as exosome therapeutics, which are designed to deliver a range of therapeutic payloads, including RNA and proteins, directly to target cells. This technology has the potential to enhance the efficacy and safety of therapies while minimizing side effects. Codiak's lead product candidate, exoIL-12, is being investigated in clinical trials for the treatment of various forms of cancer. The company aims to unlock the full potential of exosomes as a therapeutic platform, positioning itself as a leader in the rapidly evolving field of exosome-based medicine. With a commitment to scientific excellence and innovation, Codiak is dedicated to improving patient outcomes through its groundbreaking therapies.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Cambridge, Massachusetts, USA",
    "founded": "2015",
    "website": "https://www.codiakbiosciences.com",
    "ceo": "Douglas E. Williams",
    "social_media": {
        "twitter": "https://twitter.com/CodiakBio",
        "linkedin": "https://www.linkedin.com/company/codiak-biosciences/"
    },
    "investor_relations": "https://investors.codiakbiosciences.com",
    "key_executives": [
        {
            "name": "Douglas E. Williams",
            "position": "CEO"
        },
        {
            "name": "Amit S. N. Goyal",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Exosome Therapeutics",
            "products": [
                "exoIL-12"
            ]
        }
    ],
    "seo": {
        "meta_title": "Codiak BioSciences, Inc. | Exosome-Based Therapeutics",
        "meta_description": "Explore Codiak BioSciences, a leader in exosome-based therapeutics aimed at transforming cancer treatment and improving patient outcomes.",
        "keywords": [
            "Codiak BioSciences",
            "Exosome Therapeutics",
            "Biotechnology",
            "Cancer Treatment",
            "RNA Delivery",
            "Therapeutics"
        ]
    },
    "faq": [
        {
            "question": "What is Codiak known for?",
            "answer": "Codiak is known for its innovative exosome-based therapeutics aimed at treating cancer and other serious diseases."
        },
        {
            "question": "Who is the CEO of Codiak?",
            "answer": "Douglas E. Williams is the CEO of Codiak BioSciences."
        },
        {
            "question": "Where is Codiak headquartered?",
            "answer": "Codiak is headquartered in Cambridge, Massachusetts, USA."
        },
        {
            "question": "What are Codiak's main products?",
            "answer": "Codiak's main product candidate is exoIL-12, which is in clinical trials for cancer treatment."
        },
        {
            "question": "When was Codiak founded?",
            "answer": "Codiak was founded in 2015."
        }
    ],
    "competitors": [
        "EDIT",
        "CRSP",
        "ALNY"
    ],
    "related_stocks": [
        "AMGN",
        "REGN",
        "GILD",
        "BMY"
    ]
}